<scp>Perceptions of anti‐obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE</scp> Study
PwO and HCPs are interested in new AOM options, but educational gaps remain as a barrier to recommended multimodal chronic care. Ongoing education that includes the known effectiveness and safety data of newer AOMs and pending outcome trials could improve shared decision-making in obesity care.
Authors
- Kristen King‐Concialdi
- Scott Kahan (ORCID: https://orcid.org/0000-0002-3080-0661)
- Kathleen Marie Beusterien (ORCID: https://orcid.org/0000-0001-7786-5422)
- Sheila Drakeley (ORCID: https://orcid.org/0000-0002-3779-2377)
- Rekha B. Kumar (ORCID: https://orcid.org/0000-0003-1123-4059)
- Jiat Ling Poon (ORCID: https://orcid.org/0000-0001-7038-2102)
- Kimberly A. Gudzune (ORCID: https://orcid.org/0000-0002-7782-1769)
- Tracy J. Sims (ORCID: https://orcid.org/0000-0001-6822-2927)
- Lee M. Kaplan (ORCID: https://orcid.org/0000-0002-6301-2696)
- Julia P. Dunn (ORCID: https://orcid.org/0000-0001-9561-0183)
- Jamy D. Ard (ORCID: https://orcid.org/0000-0002-1643-6795)
- Nadia N. Ahmad
- Hong Kan
Institutions
- Dartmouth College (US)
- Oracle (United States) (US)
- Johns Hopkins University (US)
- Eli Lilly (United States) (US)
- George Washington University (US)
- Cornell University (US)
- Johns Hopkins Medicine (US)
- Wake Forest University (US)
Publication Details
- Journal
- Obesity
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1002/oby.24290
- Citations
- 9
- Primary Topic
- Pharmacology and Obesity Treatment
- Type
- article
- Field-Weighted Citation Impact
- 12.55
Funders
- Eli Lilly and Company